L1 Health

L1H is part of LetterOne group (L1), a privately-owned evergreen investment firm established in 2013 with approximately $20bn AuM, led by former CEOs and international businesspeople. We buy-and-build investments that stand the test of time and create value for all of our partners and stakeholders. Our investments support 120,000 jobs globally.

We are differentiated by our long-term approach to investing with a focus on businesses with significant potential to create societal benefit. We bring an industrial perspective to investing in long-term trends with the goal of "Building Businesses that Matter". L1H is exclusively focused on Healthcare, which has allowed us to build a strong industrial network and deep expertise in the sub-sectors we commit to. Our long-term perspective and sectorial expertise enables us to underwrite and support investment theses that involve transformational strategies with longer payback periods, the benefit of which is particularly acute in healthcare.

Our Advisory Board brings together distinguished leaders in the healthcare industry, including Dr. Franz Humer (former CEO and Chair of Roche), Rolf Classon (Board Member of Catalent and Fresenius Medical Care, and former CEO of Bayer Healthcare) and Dr. Annalisa Jenkins (former SVP R&D at Merck Serono). Our Advisory Board works proactively with the L1H Team to support the development of our portfolio companies.